Tempus AI, Inc. (TEM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript
Tempus AI, Inc. (NASDAQ:TEM ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Liz Krutoholow – Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Rachel Vatnsdal – JPMorgan Michael Ryskin – Bank of America Daniel Brennan – TD Cowen Ryan MacDonald – Needham Andrew Brackmann – William Blair Operator Thank you for standing by. My name is Briana, and I will be your conference operator today.
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
TEM's third-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
Tempus: Attempting To Lead The AI Revolution In Healthcare
Tempus AI, Inc, a healthcare technology company, has shown DECENT gains since its listing in June, outperforming the Nasdaq and AI-themed stock portfolios. TEM aims to leverage AI and ML and revolutionize healthcare diagnostics, a space which has large gaps and is relatively untapped. Despite an impressive revenue profile and a burgeoning data licensing vertical, TEM remains a long way off profitability and faces high operating cash burn and SG&A expenses.
Tempus Stock Up Following Collaboration Expansion in Oncology R&D
TEM's latest expanded partnership is likely to leverage multimodal real-world datasets and biological model systems in oncology R&D.
Biotech Stock Soars 60% in 2024: Cathie Wood's Bold Investment
In just ten days, shares of the mid-cap healthcare stock Tempus AI NASDAQ: TEM have gone from down 4% to up nearly 60% in 2024. Famed investor Cathie Wood recently increased her allocation to the company through the ARK Invest family of funds.
Why Tempus AI Stock Skyrocketed Nearly 22% Today
The recently listed company expanded its shareholding in a biotech. It now owns over 19% of biotech Personalis' common equity.
Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'
Tempus AI provides an end-to-end diagnostic platform connecting clinical, molecular, and image data for physicians and pharmaceutical companies. The company's key competitive advantages include broad data collection, a genomics platform, and intelligent diagnostics, positioning Tempus uniquely in the healthcare technology industry. Recent financial results show 25% year-over-year revenue growth, with Softbank's investment indicating disruptive potential in healthcare diagnostics and precision medicine.
Tempus AI Has Massive Market Opportunity For This Healthcare Technology, Bullish Analyst Says
William Blair initiated coverage on Tempus AI, Inc TEM, citing the company's ‘differentiated approach and business model.'
Why Wall Street Is Bullish on Healthcare Tech Stock Tempus AI
Several analysts kicked off coverage of Tempus AI (TEM) with bullish comments, anticipating gains from the biotech company's applications of artificial intelligence (AI) to healthcare.
Buy this healthcare company's stock because it's an AI play, analysts say
A number of Wall Street analysts on Tuesday made bullish calls on the shares of a newly public healthcare company that uses artificial intelligence to differentiate itself in the cancer-diagnostics space.
Wall Street analysts bullish on genetic testing firm Tempus AI
Wall Street brokerages started covering SoftBank Group-backed Tempus AI on a bullish note on Tuesday, betting that the company's AI-powered library of clinical and molecular data could lead to more powerful diagnostic and test kits.
IPO Watch: 3 New Stocks Worth a Strong Look
The market for initial public offerings (IPOs), featuring promising new IPOs, has rebounded strongly in 2024, with the number of offerings surpassing last year's total by 40%. The combined valuation of this year's IPOs has more than doubled compared to the previous year, sparking speculation about future public offerings.
